Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Clean air trial hopes to ease breathing for rare lung disease patients

NCT ID NCT07417267

Symptom relief Sponsor: University of Cyprus Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether using HEPA air purifiers at home can reduce respiratory symptoms and improve lung function in children and adults with Cystic Fibrosis (CF) or Primary Ciliary Dyskinesia (PCD). Participants will have two purifiers installed in their home and will undergo lung function tests and symptom checks over several months. The goal is to see if cleaner indoor air makes a real difference in their daily breathing and overall health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 62 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥6 years * Physician-confirmed diagnosis of CF or PCD, based on internationally accepted criteria. PCD diagnosis will be based on either a) a positive genetic test (bi-allelic disease-causing mutations) or b) TEM class 1 defect, as defined by the European Respiratory Society and American Thoracic Society guidelines for the diagnosis of PCD. CF diagnosis will be based on the diagnostic criteria of the European Cystic Fibrosis Society Patient Registry including: (a) two sweat chloride test values of at least 60 mmol/L, or (b) one sweat chloride test value of at least 60 mmol/L and two disease-causing CFTR mutations, or (c) typical CF features at clinical presentation and two disease-causing CFTR mutations if sweat chloride test value was less than 60 mmol/L or not reported. * Residing in a main household in Cyprus for at least 5 days per week during the study period. * Willingness and ability to provide informed consent (or approval with guardian consent for minors). Exclusion Criteria: * Active smoking * Hospitalization for any condition during the study period or lack of internet access, which is required for continuous data transmission

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cystic fibrosis (CF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cystic fibrosis primary ciliary dyskinesia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cystic fibrosis (CF) Primary ciliary dyskinesia (PCD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical School, University of Cyprus

    Nicosia, Aglantzia, 2029, Cyprus

More trials for these conditions

Other studies related to the condition(s) this trial covers.